Overview Safety and Efficacy of Intranasal Epinephrine After Administration of ARS -1 in Subjects With Frequent Urticaria Flares Status: Recruiting Trial end date: 2022-11-01 Target enrollment: Participant gender: Summary Determine the effect of ARS-1 on a patient reported pruritus/hive score Phase: Phase 2 Details Lead Sponsor: ARS Pharmaceuticals, Inc.